Cargando…
Photoactivatable prodrug for simultaneous release of mertansine and CO along with a BODIPY derivative as a luminescent marker in mitochondria: a proof of concept for NIR image-guided cancer therapy
Controlled and efficient activation is the crucial aspect of designing an effective prodrug. Herein we demonstrate a proof of concept for a light activatable prodrug with desired organelle specificity. Mertansine, a benzoansamacrolide, is an efficient microtubule-targeting compound that binds at or...
Autores principales: | Tiwari, Rajeshwari, Shinde, Prashant S., Sreedharan, Sreejesh, Dey, Anik Kumar, Vallis, Katherine A., Mhaske, Santosh B., Pramanik, Sumit Kumar, Das, Amitava |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179275/ https://www.ncbi.nlm.nih.gov/pubmed/34164035 http://dx.doi.org/10.1039/d0sc06270g |
Ejemplares similares
-
Photoactivatable BODIPYs for Live-Cell PALM
por: Zhang, Yang, et al.
Publicado: (2023) -
α(v)β(3) integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
por: Zhong, Ping, et al.
Publicado: (2017) -
Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors
por: Pinchuk, Boris, et al.
Publicado: (2016) -
Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022) -
Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV)
Anticancer Prodrugs
por: Shi, Huayun, et al.
Publicado: (2018)